Loading...
XSHG
600216
Market cap2.07bUSD
Jul 29, Last price  
15.46CNY
1D
1.38%
1Q
15.98%
Jan 2017
21.92%
Name

Zhejiang Medicine Co Ltd

Chart & Performance

D1W1MN
P/E
34.60
P/S
1.91
EPS
0.45
Div Yield, %
0.97%
Shrs. gr., 5y
-0.10%
Rev. gr., 5y
2.59%
Revenues
7.79b
-3.96%
1,382,782,8391,884,658,7272,196,496,6402,208,825,5913,761,029,3284,183,740,7744,558,265,1734,825,968,3785,264,006,1164,932,920,2364,832,291,8324,496,662,3785,279,204,0315,692,580,3656,858,741,5807,043,927,6187,326,934,7999,129,094,4968,115,804,6487,794,145,971
Net income
430m
+18.48%
12,743,69481,643,17060,618,55656,604,978972,627,3141,213,754,8251,144,708,6941,012,476,289848,542,502452,095,249169,739,354161,801,304450,102,013253,145,602364,549,966342,772,695717,399,5641,045,322,100362,613,741429,639,626
CFO
634m
+21.84%
107,598,75325,143,347169,506,018227,672,9671,199,977,1811,465,089,3911,316,312,173912,753,822807,488,234655,086,217549,899,398106,539,172336,135,774503,468,945579,907,748447,249,2871,256,721,9801,136,655,957520,603,490634,311,163
Dividend
Jul 10, 20240.15 CNY/sh

Profile

Zhejiang Medicine Co., Ltd. produces and sells life nutrition and pharmaceutical products in China. The company offers life nutrition products, such as synthetic vitamin E, vitamin A, natural vitamin E, vitamin H, vitamin D3, coenzyme Q10, carotene, cantharidin, lutein, lycopene, and other vitamins and vitamin products. It also provides pharmaceutical manufacturing products, including anti-drug resistant antibiotics, anti-malaria and other pharmaceutical raw materials, quinolones, and anti-drug resistant products; and pharmaceutical products comprising sugars and hormones. The company was founded in 1997 and is headquartered in Shaoxing, China.
URL
https://www.zmc.top/
IPO date
Oct 21, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,794,146
-3.96%
8,115,805
-11.10%
Cost of revenue
7,293,036
7,138,750
Unusual Expense (Income)
NOPBT
501,110
977,055
NOPBT Margin
6.43%
12.04%
Operating Taxes
86,485
128,775
Tax Rate
17.26%
13.18%
NOPAT
414,626
848,280
Net income
429,640
18.48%
362,614
-65.31%
Dividends
(163,995)
(318,492)
Dividend yield
1.60%
2.84%
Proceeds from repurchase of equity
(1,293)
BB yield
0.01%
Debt
Debt current
200,223
600,977
Long-term debt
230,868
201,426
Deferred revenue
84,158
54,112
Other long-term liabilities
1
1
Net debt
(1,195,147)
(1,082,968)
Cash flow
Cash from operating activities
634,311
520,603
CAPEX
Cash from investing activities
(464,915)
Cash from financing activities
(195,483)
43,914
FCF
291,849
98,581
Balance
Cash
1,788,337
1,885,371
Long term investments
(162,098)
Excess cash
1,236,532
1,479,580
Stockholders' equity
6,361,113
8,646,938
Invested Capital
9,264,789
8,980,668
ROIC
4.54%
9.94%
ROCE
4.77%
9.34%
EV
Common stock shares outstanding
954,755
958,544
Price
10.73
-8.21%
11.69
-31.56%
Market cap
10,244,518
-8.57%
11,205,378
-31.54%
EV
9,405,049
10,572,387
EBITDA
1,226,088
1,658,658
EV/EBITDA
7.67
6.37
Interest
28,336
33,112
Interest/NOPBT
5.65%
3.39%